Pradžia › Mielofibrozė › Masčusetsas
Mielofibrozė klinikiniai tyrimai Masčusetsas
13 tyrimai dėl Mielofibrozė ieško dalyvių vietose Masčusetsas.
Miestai Masčusetsas
Oficialus tyrimo tekstas (anglų kalba)
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- Massachusetts General Hospital, Boston
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT04176198A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Tufts Medical Center, Boston
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT07623161A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-17 · NCT06343805A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
- Massachusetts General Hospital (Data Collection Only), Boston
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-28 · NCT06773195A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Brigham and Women's Hospital, Boston
Renkami dalyviai1 fazėLaukiami sveiki savanoriai
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-07-28 · NCT07020533Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- Massachusetts General Hospital, Boston
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-22 · NCT07441694Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Dana Farber Cancer Institute, Boston
Renkami dalyviai1 fazė
Amžius 13 ir vyresni · Visoms lytims · Atnaujinta 2026-05-05 · NCT04771572A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Dana Farber Cancer Institute, Boston
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-04-17 · NCT06034002Momelotinib During and After HCT in Myelofibrosis
- Massachusetts General Hospital, Boston
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-31 · NCT07104799A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
Renkami dalyviai2 fazė
Amžius nuo 18 iki 66 · Visoms lytims · Atnaujinta 2026-03-17 · NCT06859424CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- DFCI/BWH Brigham and Women's Hospital, Boston
Renkami dalyviai2 fazėLaukiami sveiki savanoriai
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-03-10 · NCT06059391SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2025-10-28 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Dana Farber Cancer Institute, Boston
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-09-25 · NCT06479135Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.